Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $43.82 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2025 revenue of $196-210 million, versus the consensus of $204.4 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Eco Wave Power featured in Nvidia blog on wave energy and AI